BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...
Drug
Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials
Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...
Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China
Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval...
ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection
ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...
Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...
Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment
Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...
InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...
AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA
AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...
Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM
The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...
BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...
BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments
The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...
Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment
US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment
Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...
Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...
Boan Biotech Secures FDA Orphan Drug Designations for Pancreatic Cancer Treatments
China-based Boan Biotech (HKG: 6955) has announced that its novel antibody BA1105 and antibody-drug conjugate...
Gilead’s Kite Receives FDA Nod to Add Overall Survival Data to Yescarta for Large B-Cell Lymphoma
Gilead Sciences Inc. (NASDAQ: GILD) subsidiary Kite has received approval from the U.S. Food and...